Why is Sun Pharma betting $11.75B on a struggling US drugmaker?

In one of the biggest outbound acquisitions ever attempted by an Indian company, Sun Pharmaceutical Industries has decided to buy Organon & Co. for $14 a share in an all-cash deal valued at $11.8 billion The logic of the deal is easy to state and harder to execute as Sun is not buying a fast-growing asset, but a scaled global platform with meaningful cash flow, a large commercial footprint and a huge debt load. Sun is planning to expand in women's health, biosimilars and innovative medicines, while Organon brings more than 70 products across women's health and general medicines in 140 countries.